Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib + Capecitabine for HER2+ Advanced Gastric/GEJ/Esophageal Cancer with Brain Metastases
NCT06374888Phase 2Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Sep 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of neratinib in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), esophagogastric junction adenocarcinoma (GEJA), sponsored by Convalife Pharmaceutical. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT06374888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06374888.